Meng Pan, Han Yuanshan, Yang Qin, Yang Hui, Zhu Qing, Lin Xiaoyuan, Zhang Xiuli, Zhao Hongqing, Liu Zhuo, Liu Jian, Tang Lin, Luo Weixu, Wang Yuhong
Institute of Innovation and Applied Research in Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China.
The First Affiliated Hospital, Hunan University of Chinese Medicine, Changsha, Hunan 410007, China.
Evid Based Complement Alternat Med. 2018 Nov 18;2018:3967642. doi: 10.1155/2018/3967642. eCollection 2018.
Diagnosis with breast cancer is a major life event that elicits increases in depressive symptoms for up to 50% of women. Xiaoyao Kangai Jieyu Fang (XYKAJY) is derived from a canonical TCM formula, Xiaoyao San (XYS), which has a history of nearly 1000 years for treating depression. The aim of this study was to investigate whether XYKAJY alleviates depression-like behavior and breast tumor proliferation in breast cancer mice then explore the mechanisms underlying its action on HPA axis and hippocampal plasticity further. XYKAJY was treated at the high dose of 1.95 g/mL and 0.488 g/mL, after 21 days of administration. Different behaviors, monoamine neurotransmitters, tumor markers, and the index of HPA axis were detected to evaluate depressive-like symptoms of breast cancer mice. Also, the pathological changes of the tumor, hippocampus, and the expressions of GR, NR2A, NR2B, CAMKII, CREB, and BDNF were detected. In this study, XYKAJY formulation significantly improved the autonomic behavior, reduced the incubation period of feeding, and reversed the typical depressive-like symptoms in breast cancer mice. Also, it reduced the content of CORT, ACTH, CRH, and CA125, CA153, CEA in the blood, protected the pathological changes of the hippocampus and tumor, upregulated the expression of GR, CREB, and BDNF in the hippocampus, and significantly decreased the expression of NR2A, NR2B, and CaMKII. These results provide direct evidence that XYKAJY effectively alleviates depression-like behaviors and tumor proliferation in vehicle mice with ameliorates hippocampus synaptic plasticity dysfunctions.
乳腺癌的诊断是一件重大的人生事件,会使多达50%的女性出现抑郁症状增加的情况。逍遥抗癌解郁方(XYKAJY)源自经典的中医方剂逍遥散(XYS),逍遥散治疗抑郁症已有近千年历史。本研究的目的是调查XYKAJY是否能减轻乳腺癌小鼠的抑郁样行为和乳腺肿瘤增殖,然后进一步探讨其对下丘脑-垂体-肾上腺(HPA)轴和海马可塑性作用的潜在机制。给药21天后,以1.95 g/mL和0.488 g/mL的高剂量给予XYKAJY。检测不同行为、单胺类神经递质、肿瘤标志物和HPA轴指标,以评估乳腺癌小鼠的抑郁样症状。此外,还检测了肿瘤、海马的病理变化以及糖皮质激素受体(GR)、N-甲基-D-天冬氨酸受体2A(NR2A)、N-甲基-D-天冬氨酸受体2B(NR2B)、钙/钙调蛋白依赖性蛋白激酶II(CaMKII)、环磷腺苷效应元件结合蛋白(CREB)和脑源性神经营养因子(BDNF)的表达。在本研究中,XYKAJY制剂显著改善了自主行为,缩短了进食潜伏期,并逆转了乳腺癌小鼠典型的抑郁样症状。此外,它降低了血液中皮质酮(CORT)、促肾上腺皮质激素(ACTH)、促肾上腺皮质激素释放激素(CRH)以及糖类抗原125(CA125)、糖类抗原153(CA153)、癌胚抗原(CEA)的含量,保护了海马和肿瘤的病理变化,上调了海马中GR、CREB和BDNF的表达,并显著降低了NR2A、NR2B和CaMKII的表达。这些结果提供了直接证据,表明XYKAJY能有效减轻模型小鼠的抑郁样行为和肿瘤增殖,并改善海马突触可塑性功能障碍。